Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5236 AL 5250

Reversal of cognitive decline: a novel therapeutic program

Bredesen DE.

Aging (Albany NY). 2014 Sep;6(9):707-17. doi: 10.18632/aging.100690.

[Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?]

García-Casares N, García-Arnés JA, Gómez-Huelgas R, Valdivielso-Felices P, García-Arias C, González-Santos P.

Rev Neurol. 2014 Dec 1;59(11):517-24.

How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story

Richardson A, Galvan V, Lin AL, Oddo S.

Exp Gerontol. 2015 Aug;68:51-8. doi: 10.1016/j.exger.2014.12.002. Epub 2014 Dec 3.

Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services

Wattmo C, Londos E, Minthon L.

Clin Interv Aging. 2014 Nov 14;9:1951-62. doi: 10.2147/CIA.S71709. eCollection 2014.

A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease

D'Onofrio G, Sancarlo D, Addante F, Ciccone F, Cascavilla L, Paris F, Elia AC, Nuzzaci C, Picoco M, Greco A, Panza F, Pilotto A.

Int J Geriatr Psychiatry. 2015 Sep;30(9):965-75. doi: 10.1002/gps.4247. Epub 2014 Dec 12.

A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD)

Ballard C, Thomas A, Gerry S, Yu LM, Aarsland D, Merritt C, Corbett A, Davison C, Sharma N, Khan Z, Creese B, Loughlin P, Bannister C, Burns A, Win SN, Walker Z; MAIN-AD investigators.

J Am Med Dir Assoc. 2015 Apr;16(4):316-22. doi: 10.1016/j.jamda.2014.11.002. Epub 2014 Dec 15.

Searching for disease-modifying drugs in AD: can we combine neuropsychological tools with biological markers?

Caraci F, Castellano S, Salomone S, Drago F, Bosco P, Di Nuovo S.

CNS Neurol Disord Drug Targets. 2014 Feb;13(1):173-86. doi: 10.2174/18715273113129990103.

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group.

N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

Cognitive-behavioural group therapy improves a psychophysiological marker of stress in caregivers of patients with Alzheimer's disease

Aboulafia-Brakha T, Suchecki D, Gouveia-Paulino F, Nitrini R, Ptak R.

Aging Ment Health. 2014;18(6):801-8. doi: 10.1080/13607863.2014.880406. Epub 2014 Feb 5.

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M.

J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191.

Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents

Ambure P, Roy K.

Expert Opin Drug Discov. 2014 Jun;9(6):697-723. doi: 10.1517/17460441.2014.909404. Epub 2014 Apr 23.

[Progress of dementia medicine: Special reference to Alzheimer's disease]

Utsumi K.

Hokkaido Igaku Zasshi. 2014 May;89(1):21-3.

Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials

Jia Q, Deng Y, Qing H.

Biomed Res Int. 2014;2014:837157. doi: 10.1155/2014/837157. Epub 2014 Jul 17.

Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin

Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, Tüscher O, Fellgiebel A.

Neurology. 2014 Nov 18;83(21):1930-5. doi: 10.1212/WNL.0000000000001017. Epub 2014 Oct 24.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias